Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA tells industry that proposal on trials also can’t use SPA-like process.

Advertisement

Related Content

Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
FDA Prescription Drug User Fee Program Will Get OIG Appraisal
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
PDUFA Negotiations End With Differences To Resolve In Commitment Letter
PDUFA Negotiations End, Approval Process Ongoing
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
PDUFA VI: Innovative Trial Design Proposal Includes Modeling, Simulation
FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?
Does PDUFA Need A Haircut? FDA Ponders Trimming Its Responsibilities
PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work

Topics

Advertisement
UsernamePublicRestriction

Register

PS078042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel